With reference to the stock exchange announcement from
The HeROPA trial is randomized, double blind and placebo controlled, investigating the efficacy and safety of the novel, oral drug candidate HRO350 for the treatment of mild-to-moderate psoriasis. The HeROPA trial is ongoing in 5 countries in
The HeROPA trial has had competitive recruitment at over 60 sites in the 5 countries to recruit the 519 patients. Fully recruiting this very large study is a result of impressive efforts from over 60 sites across five countries. The final recruited patients will be dosed in the next few weeks, and first data-readout will be when all patients have been treated for 6 months, mid 2024.
We are grateful for the participation of dermatology clinics and patients with mild-to-moderate psoriasis throughout
"We are very pleased to announce that our HeROPA clinical trial is now fully recruited. This is a major milestone for Arctic Bioscience and a result of great team effort by the employees in Arctic Bioscience, our
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
CEO
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---recruitment-completed-in-the-phase-iib-heropa-clinical-trial,c3910574
(c) 2024 Cision. All rights reserved., source